• BioLargo CEO Dennis Calvert told shareholders in a May 5 town hall that current market cap of about USD 50 million implies no value for several operating units beyond its stake in Clyra Medical, which he valued at roughly USD 100 million, implying BioLargo position worth about USD 50 million.
• Calvert highlighted an MOU with Aquatech to pursue PFAS treatment projects using BioLargo AEC technology, describing joint customer work as active while declining to forecast timing for contract wins.
• He said first municipal AEC installation in Lake Stockholm, New Jersey is producing compliant drinking water under a temporary permit, with NJDEP and federal involvement now focused on supervising data collection toward a long-term permit.
• On Clyra, he cited first commercial stocking order shipped in February, a new distribution agreement with Al Hikma covering Middle East and North Africa markets, and expected FDA filing for a larger distributor launch that he framed as about 100 days from submission, with a fall-season target for launch.
• Calvert said BioLargo won a USD 1.2 million engineering contract tied to mineral extraction IP, with potential next phases in the approximate range of USD 10 million for a pilot and more than USD 40 million for a build-out.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLargo Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-014996), on May 06, 2026, and is solely responsible for the information contained therein.